Lucimycin

CAS: 13058-67-8

Ref. 3D-FL177686

Informação sobre produto

• Nome: Lucimycin
• Sinónimos: (1R,3S,5R,7R,8E,14E,16E,18E,20E,22R,24S,25R,26S)-22-[(3-Amino-3,6-dideoxy-β-<span class="text-smallcaps">D</span>-mannopyranosyl)oxy]-12-butyl-1,3,26-trihydroxy-10-oxo-6,11,28-trioxatricyclo[22.3.1.0^5,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid, (8E)-22-[(3-amino-3,6-dideoxy-beta-D-glycero-hexopyranosyl)oxy]-12-butyl-1,3,26-trihydroxy-10-oxo-6,11,28-trioxatricyclo[22.3.1.0~5,7~]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid, 6,11,28-Trioxatricyclo(22.3.1.05,7)octacowq-8,14,16,18,20-pentaene-25-carboxylic acid, 22-((3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-12-butyl-1,3,26-trihydroxy-10-oxo-, 6,11,28-Trioxatricyclo[22.3.1.0^5,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid, 22-[(3-amino-3,6-dideoxy-β-<span class="text-smallcaps">D</span>-mannopyranosyl)oxy]-12-butyl-1,3,26-trihydroxy-10-oxo-, 6,11,28-Trioxatricyclo[22.3.1.0^5,7]octacosane, lucensomycin deriv., Antibiotic 1163 F.I., Antibiotic FI 1163, Antibiotic obtained from cultures of Streptomyces lucensis, or the same substance produced by any other means, Etruscomicina, Etruscomycin, Fi 1163, Leucensomycin, Lucensomycin, Nsc 143257, Stereoisomer of 22-((3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-12-butyl-1,3,26-trihydroxy-10-oxo-6,11,28-trioxatricyclo(33.3.1.05,7)octacosa-8,14,16,18,20-pentaene-25-carboxylic acid, 6,11,28-Trioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid, 22-[(3-amino-3,6-dideoxy-β-D-mannopyranosyl)oxy]-12-butyl-1,3,26-trihydroxy-10-oxo-, 6,11,28-Trioxatricyclo[22.3.1.05,7]octacosane, lucensomycin deriv., (1R,3S,5R,7R,8E,14E,16E,18E,20E,22R,24S,25R,26S)-22-[(3-Amino-3,6-dideoxy-β-D-mannopyranosyl)oxy]-12-butyl-1,3,26-trihydroxy-10-oxo-6,11,28-trioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid

Descrição

Lucimycin is a polyene antibiotic that has been shown to have strong anti-infective properties against microbial infection. It is active against both Gram-positive and Gram-negative bacteria, including resistant mutants. Lucimycin has been shown to interact with hydroxyl groups on the bacterial cell membrane, which may be due to its ability to form polymers. The polyene structure also allows for binding to the DNA polymerase of the bacterial cell. Lucimycin has been found to be effective in treating choroidal neovascularization, a condition where new blood vessels grow on or near the retina and can lead to blindness. This drug also interacts with sodium citrate and proton pumps in the intestine, which may be responsible for its ability to treat diarrhoea.

• Marca: Biosynth

Propriedades químicas

• Peso molecular: 707.8 g/mol
• Fórmula: C₃₆H₅₃NO₁₃
• Pureza: Min. 95%